Comparison of lycopene and fluvastatin effects on atherosclerosis induced by a high-fat diet in rabbits

Nutrition

Volumn 24, Issue 10, 2008, Pages 1030-1038

  Hu, Min Yu ^a   Li, Yi Lin ^a   Jiang, Chong He ^b   Liu, Zhao Qian ^a   Qu, Shu Lin ^b   Huang, Yi Ming ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b HUNAN NORMAL UNIVERSITY   (China)

Author keywords

Atherogenesis; Fluvastatin; Lycopene; Rabbit

Indexed keywords

FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 1; LOW DENSITY LIPOPROTEIN; LYCOPENE; MALONALDEHYDE; NITRIC OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; LIPID DIET; MALE; NONHUMAN; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN BLOOD LEVEL; WEIGHT CHANGE;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTIOXIDANTS; ATHEROSCLEROSIS; CAROTENOIDS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIETARY FATS; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS, MONOUNSATURATED; INDOLES; INTERLEUKIN-1; LIPID METABOLISM; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; RABBITS; RANDOM ALLOCATION; TIME FACTORS; TRIGLYCERIDES;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 50549087174     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nut.2008.05.006     Document Type: Article

References (44)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362 (1993) 801-809
2. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
3. Crowther M.A. Pathogenesis of atherosclerosis. Hematology (Am Soc Hematol Educ Program) (2005) 436-441
4. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
5. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 23-33
6. Tunon J., Blanco-Colio L.M., Martin-Ventura J.L., and Egido J. Intensive treatment with statins and the progression of cardiovascular diseases: the beginning of a new era?. Nephrol Dial Transplant 19 (2004) 2696-2699
7. Willerson J.T., and Ridker P.M. Inflammation as a cardiovascular risk factor. Circulation 109 (2004) II2-II10
8. International Atherosclerosis Society. International Atherosclerosis Society harmonized guidelines on prevention of atherosclerotic cardiovascular disease. Full Report (2003) 1-74. http://www.athero.org www.athero.org
9. Nguyen M.L., and Schwartz S.J. Lycopene: chemical and biological properties. Food Technol 53 (1999) 38-45
10. Agarwal S., and Rao A.V. Tomato lycopene and its role in human health and chronic diseases. CMAJ 163 (2000) 739-744
11. Hadley C.W., Clinton S.K., and Schwartz S.J. The consumption of processed tomato products enhances plasma lycopene concentrations in association with a reduced lipoprotein sensitivity to oxidative damage. J Nutr 133 (2003) 727-732
12. Rissanen T.H., Voutilainen S., Nyyssonen K., Salonen R., Kaplan G.A., and Salonen J.T. Serum lycopene concentrations and carotid atherosclerosis: the Kuopio Ischaemic Heart Disease Risk Factor Study. Am J Clin Nutr 77 (2003) 133-138
13. Canene-Adams K., Campbell J.K., Zaripheh S., Jeffery E.H., and Erdman Jr. J.W. The tomato as a functional food. J Nutr 135 (2005) 1226-1230
14. Omoni A.O., and Aluko R.E. The anti-carcinogenic and anti-atherogenic effects of lycopene: a review. Trends Food Sci Tech 16 (2005) 344-350
15. Brady W.E., Mares-Perlman J.A., Bowen P., and Stacewicz-Sapuntzakis M. Human serum carotenoid concentrations are related to physiologic and lifestyle factors. J Nutr 126 (1996) 129-137
16. Rissanen T.H., Voutilainen S., Nyyssonen K., Salonen R., and Salonen J.T. Low plasma lycopene concentration is associated with increased intima-media thickness of the carotid artery wall. Arterioscler Thromb Vasc Biol 20 (2000) 2677-2681
17. Klipstein-Grobusch K., Launer L.J., Geleijnse J.M., Boeing H., Hofman A., and Witteman J.C. Serum carotenoids and atherosclerosis. The Rotterdam Study. Atherosclerosis 148 (2000) 49-56
18. Rissanen T.H., Voutilainen S., Nyyssonen K., and Salonen J.T. Lycopene, atherosclerosis, and coronary heart disease. Exp Biol Med (Maywood) 227 (2002) 900-907
19. Sesso H.D., Liu S., Gaziano J.M., and Buring J.E. Dietary lycopene, tomato-based food products and cardiovascular disease in women. J Nutr 133 (2003) 2336-2341
20. Kaliora A.C., Dedoussis G.V., and Schmidt H. Dietary antioxidants in preventing atherogenesis. Atherosclerosis 187 (2006) 1-17
21. Roldan-Gutierrez J.M., and Luque de Castro M.D. Lycopene: the need for better methods for characterization and determination. Trends Anal Chem 26 (2007) 163-170
22. Watson T.D., Butterwick R.F., McConnell M., and Markwell P.J. Development of methods for analyzing plasma lipoprotein concentrations and associated enzyme activities and their use to measure the effects of pregnancy and lactation in cats. Am J Vet Res 56 (1995) 289-296
23. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
24. Miller N.J., Rice-Evans C., Davies M.J., Gopinathan V., and Milner A. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci (Lond) 84 (1993) 407-412
25. Wills E.D. Mechanisms of lipid peroxide formation in animal tissues. Biochem J 99 (1966) 667-676
26. Wang J.J., Liu X.Z., Zhuang Y.Y., and Li L.Y. Correlation between susceptibility of LDL subfractions to in vitro oxidation and in vivo oxidized LDL. Clin Biochem 33 (2000) 71-73
27. Yu L.Y., Lin B., Zhang Z.L., and Guo L.H. Direct transfer of A20 gene into pancreas protected mice from streptozotocin-induced diabetes. Acta Pharmacol Sin 25 (2004) 721-726
28. Li L., Messas E., Batista Jr. E.L., Levine R.A., and Amar S. Porphyromonas gingivalis infection accelerates the progression of atherosclerosis in a heterozygous apolipoprotein E-deficient murine model. Circulation 105 (2002) 861-867
29. Weisburger J.H. Lycopene and tomato products in health promotion. Exp Biol Med (Maywood) 227 (2002) 924-927
30. Wu K., Schwartz S.J., Platz E.A., Clinton S.K., Erdman Jr. J.W., Ferruzzi M.G., et al. Variations in plasma lycopene and specific isomers over time in a cohort of U.S. men. J Nutr 133 (2003) 1930-1936
31. Frederiksen H., Rasmussen S.E., Schroder M., Bysted A., Jakobsen J., Frandsen H., et al. Dietary supplementation with an extract of lycopene-rich tomatoes does not reduce atherosclerosis in Watanabe Heritable Hyperlipidemic rabbits. Br J Nutr 97 (2007) 6-10
32. Berliner J.A., Navab M., Fogelman A.M., Frank J.S., Demer L.L., Edwards P.A., et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 91 (1995) 2488-2496
33. Shi J., and Le Maguer M. Lycopene in tomatoes: chemical and physical properties affected by food processing. Crit Rev Biotechnol 20 (2000) 293-334
34. Mayne S.T., Cartmel B., Silva F., Kim C.S., Fallon B.G., Briskin K., et al. Plasma lycopene concentrations in humans are determined by lycopene intake, plasma cholesterol concentrations and selected demographic factors. J Nutr 129 (1999) 849-854
35. Asberg A., and Holdaas H. Fluvastatin and fluvastatin extended release: a clinical and safety profile. Expert Rev Cardiovasc Ther 2 (2004) 641-652
36. Morita H., Saito Y., Ohashi N., Yoshikawa M., Katoh M., Ashida T., et al. Fluvastatin ameliorates the hyperhomocysteinemia-induced endothelial dysfunction: the antioxidative properties of fluvastatin. Circ J 69 (2005) 475-480
37. Lamarche B., Tchernof A., Moorjani S., Cantin B., Dagenais G.R., Lupien P.J., et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 95 (1997) 69-75
38. Parthasarathy S. Mechanisms by which dietary antioxidants may prevent cardiovascular diseases. J Med Food 1 (1998) 45-51
39. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. Circulation 106 (2002) 3143-3421
40. Qiao C., Zhang K., and Xia J. Influence of oxidized low density lipoprotein on the proliferation of human artery smooth muscle cells in vitro. J Huazhong Univ Sci Technolog Med Sci 27 (2007) 20-23
41. Uchida K. Role of reactive aldehyde in cardiovascular diseases. Free Radic Biol Med 28 (2000) 1685-1696
42. Sudano I., Spieker L.E., Hermann F., Flammer A., Corti R., Noll G., et al. Protection of endothelial function: targets for nutritional and pharmacological interventions. J Cardiovasc Pharmacol 47 suppl 2 (2006) S136-S150
43. Loppnow H., Westphal E., Buchhorn R., Wessel A., and Werdan K. Interleukin-1 and related proteins in cardiovascular disease in adults and children. Shock 16 suppl 1 (2001) 3-9
44. Chi H., Messas E., Levine R.A., Graves D.T., and Amar S. Interleukin-1 receptor signaling mediates atherosclerosis associated with bacterial exposure and/or a high-fat diet in a murine apolipoprotein E heterozygote model: pharmacotherapeutic implications. Circulation 110 (2004) 1678-1685